aluates Reports

$ 0.0

Automative

Global Non-Muscle-Invasive Bladder Cancer Treatment Market Research Report 2024

Published Date: May 2024

Report Code: QYRE-Auto-21B11592

Global Non Muscle Invasive Bladder Cancer Treatment Market Research Report 2022

BUY CHAPTERS

Global Non-Muscle-Invasive Bladder Cancer Treatment Market Research Report 2024

Code: QYRE-Auto-21B11592

Report

May 2024

Pages:73

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Ferring Pharmaceuticals

Merck

Theralase

Sesen Bio

CG Oncology

ImmunityBio

Viventia Bio Inc.

Non-Muscle-Invasive Bladder Cancer Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Non-Muscle-Invasive Bladder Cancer Treatment Market

The global Non-Muscle-Invasive Bladder Cancer Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Non-Muscle-Invasive Bladder Cancer Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Muscle-Invasive Bladder Cancer Treatment.

Report Scope

The Non-Muscle-Invasive Bladder Cancer Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Muscle-Invasive Bladder Cancer Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-Muscle-Invasive Bladder Cancer Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Non-Muscle-Invasive Bladder Cancer Treatment Market Report

Report Metric	Details
Report Name	Non-Muscle-Invasive Bladder Cancer Treatment Market
CAGR	5%
Segment by Type	Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Segment by Application	Hospitals Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Ferring Pharmaceuticals, Merck, Sesen Bio, CG Oncology, ImmunityBio, Theralase, Viventia Bio Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Muscle-Invasive Bladder Cancer Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Non-Muscle-Invasive Bladder Cancer Treatment Market report?

Ans: The main players in the Non-Muscle-Invasive Bladder Cancer Treatment Market are Ferring Pharmaceuticals, Merck, Sesen Bio, CG Oncology, ImmunityBio, Theralase, Viventia Bio Inc.

What are the Application segmentation covered in the Non-Muscle-Invasive Bladder Cancer Treatment Market report?

Ans: The Applications covered in the Non-Muscle-Invasive Bladder Cancer Treatment Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Non-Muscle-Invasive Bladder Cancer Treatment Market report?

Ans: The Types covered in the Non-Muscle-Invasive Bladder Cancer Treatment Market report are Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment, Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment, High-Risk Non-Muscle-Invasive Bladder Cancer Treatment

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment

1.2.3 Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment

1.2.4 High-Risk Non-Muscle-Invasive Bladder Cancer Treatment

1.3 Market by Application

1.3.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Perspective (2019-2030)

2.2 Non-Muscle-Invasive Bladder Cancer Treatment Growth Trends by Region

2.2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Region (2019-2024)

2.2.3 Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Region (2025-2030)

2.3 Non-Muscle-Invasive Bladder Cancer Treatment Market Dynamics

2.3.1 Non-Muscle-Invasive Bladder Cancer Treatment Industry Trends

2.3.2 Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers

2.3.3 Non-Muscle-Invasive Bladder Cancer Treatment Market Challenges

2.3.4 Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Revenue

3.1.1 Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Revenue (2019-2024)

3.1.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Non-Muscle-Invasive Bladder Cancer Treatment Revenue

3.4 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Concentration Ratio

3.4.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2023

3.5 Non-Muscle-Invasive Bladder Cancer Treatment Key Players Head office and Area Served

3.6 Key Players Non-Muscle-Invasive Bladder Cancer Treatment Product Solution and Service

3.7 Date of Enter into Non-Muscle-Invasive Bladder Cancer Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Muscle-Invasive Bladder Cancer Treatment Breakdown Data by Type

4.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Type (2019-2024)

4.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Type (2025-2030)

5 Non-Muscle-Invasive Bladder Cancer Treatment Breakdown Data by Application

5.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Historic Market Size by Application (2019-2024)

5.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)

6.2 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024)

6.4 North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)

7.2 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024)

7.4 Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)

8.2 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2019-2024)

8.4 Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)

9.2 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024)

9.4 Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size (2019-2030)

10.2 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024)

10.4 Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Ferring Pharmaceuticals

11.1.1 Ferring Pharmaceuticals Company Detail

11.1.2 Ferring Pharmaceuticals Business Overview

11.1.3 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Introduction

11.1.4 Ferring Pharmaceuticals Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

11.1.5 Ferring Pharmaceuticals Recent Development

11.2 Merck

11.2.1 Merck Company Detail

11.2.2 Merck Business Overview

11.2.3 Merck Non-Muscle-Invasive Bladder Cancer Treatment Introduction

11.2.4 Merck Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

11.2.5 Merck Recent Development

11.3 Sesen Bio

11.3.1 Sesen Bio Company Detail

11.3.2 Sesen Bio Business Overview

11.3.3 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Introduction

11.3.4 Sesen Bio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

11.3.5 Sesen Bio Recent Development

11.4 CG Oncology

11.4.1 CG Oncology Company Detail

11.4.2 CG Oncology Business Overview

11.4.3 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Introduction

11.4.4 CG Oncology Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

11.4.5 CG Oncology Recent Development

11.5 ImmunityBio

11.5.1 ImmunityBio Company Detail

11.5.2 ImmunityBio Business Overview

11.5.3 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Introduction

11.5.4 ImmunityBio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

11.5.5 ImmunityBio Recent Development

11.6 Theralase

11.6.1 Theralase Company Detail

11.6.2 Theralase Business Overview

11.6.3 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Introduction

11.6.4 Theralase Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

11.6.5 Theralase Recent Development

11.7 Viventia Bio Inc.

11.7.1 Viventia Bio Inc. Company Detail

11.7.2 Viventia Bio Inc. Business Overview

11.7.3 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Introduction

11.7.4 Viventia Bio Inc. Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

11.7.5 Viventia Bio Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Ferring Pharmaceuticals

Merck

Theralase

Sesen Bio

CG Oncology

ImmunityBio

Viventia Bio Inc.

List of Tables

Table 1. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment

Table 3. Key Players of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment

Table 4. Key Players of High-Risk Non-Muscle-Invasive Bladder Cancer Treatment

Table 5. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Region (2019-2024)

Table 9. Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Region (2025-2030)

Table 11. Non-Muscle-Invasive Bladder Cancer Treatment Market Trends

Table 12. Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers

Table 13. Non-Muscle-Invasive Bladder Cancer Treatment Market Challenges

Table 14. Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints

Table 15. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Players (2019-2024)

Table 17. Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Muscle-Invasive Bladder Cancer Treatment as of 2023)

Table 18. Ranking of Global Top Non-Muscle-Invasive Bladder Cancer Treatment Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Non-Muscle-Invasive Bladder Cancer Treatment Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Non-Muscle-Invasive Bladder Cancer Treatment Product Solution and Service

Table 22. Date of Enter into Non-Muscle-Invasive Bladder Cancer Treatment Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Type (2019-2024)

Table 26. Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Type (2025-2030)

Table 28. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Application (2019-2024)

Table 30. Global Non-Muscle-Invasive Bladder Cancer Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share by Application (2025-2030)

Table 32. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 47. Ferring Pharmaceuticals Company Detail

Table 48. Ferring Pharmaceuticals Business Overview

Table 49. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Product

Table 50. Ferring Pharmaceuticals Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)

Table 51. Ferring Pharmaceuticals Recent Development

Table 52. Merck Company Detail

Table 53. Merck Business Overview

Table 54. Merck Non-Muscle-Invasive Bladder Cancer Treatment Product

Table 55. Merck Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)

Table 56. Merck Recent Development

Table 57. Sesen Bio Company Detail

Table 58. Sesen Bio Business Overview

Table 59. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Product

Table 60. Sesen Bio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)

Table 61. Sesen Bio Recent Development

Table 62. CG Oncology Company Detail

Table 63. CG Oncology Business Overview

Table 64. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Product

Table 65. CG Oncology Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)

Table 66. CG Oncology Recent Development

Table 67. ImmunityBio Company Detail

Table 68. ImmunityBio Business Overview

Table 69. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Product

Table 70. ImmunityBio Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)

Table 71. ImmunityBio Recent Development

Table 72. Theralase Company Detail

Table 73. Theralase Business Overview

Table 74. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Product

Table 75. Theralase Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)

Table 76. Theralase Recent Development

Table 77. Viventia Bio Inc. Company Detail

Table 78. Viventia Bio Inc. Business Overview

Table 79. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Product

Table 80. Viventia Bio Inc. Revenue in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024) & (US$ Million)

Table 81. Viventia Bio Inc. Recent Development

Table 82. Research Programs/Design for This Report

Table 83. Key Data Information from Secondary Sources

Table 84. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Type: 2023 VS 2030

Figure 3. Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment Features

Figure 4. Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment Features

Figure 5. High-Risk Non-Muscle-Invasive Bladder Cancer Treatment Features

Figure 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Application: 2023 VS 2030

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Others Case Studies

Figure 11. Non-Muscle-Invasive Bladder Cancer Treatment Report Years Considered

Figure 12. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Region: 2023 VS 2030

Figure 15. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Players in 2023

Figure 16. Global Top Non-Muscle-Invasive Bladder Cancer Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Muscle-Invasive Bladder Cancer Treatment as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2023

Figure 18. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Country (2019-2030)

Figure 20. United States Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Country (2019-2030)

Figure 24. Germany Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Region (2019-2030)

Figure 32. China Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Country (2019-2030)

Figure 40. Mexico Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Market Share by Country (2019-2030)

Figure 44. Turkey Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Ferring Pharmaceuticals Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

Figure 47. Merck Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

Figure 48. Sesen Bio Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

Figure 49. CG Oncology Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

Figure 50. ImmunityBio Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

Figure 51. Theralase Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

Figure 52. Viventia Bio Inc. Revenue Growth Rate in Non-Muscle-Invasive Bladder Cancer Treatment Business (2019-2024)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

Figure 55. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Lymphoma Therapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10S14319

Sun May 19 00:00:00 UTC 2024

Add to Cart

Global Gene Therapy on Cancer Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-3X14503

Sun May 19 00:00:00 UTC 2024

Add to Cart

Global Internal Radiotherapy Devices Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10C14318

Sun May 19 00:00:00 UTC 2024

Add to Cart

Global Remote Afterloading System Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-34B7845

Sun May 19 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions